<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1423">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142631</url>
  </required_header>
  <id_info>
    <org_study_id>2021-013-CH05 IIT-STS</org_study_id>
    <nct_id>NCT05142631</nct_id>
  </id_info>
  <brief_title>Fruquintinib in the Treatment of Soft Tissue Sarcoma</brief_title>
  <official_title>Single Center, Open, Single Arm Phase II Clinical Study of Fruquintinib in the Treatment of Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of Fruquintinib in patients with chemotherapy insensitive or&#xD;
      chemotherapy resistant soft tissue sarcoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is an open, single arm, single center, prospective phase II clinical study.&#xD;
      Objective:To observe the efficacy and safety of Fruquintinib in the first-line treatment of&#xD;
      desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma or&#xD;
      second-line and posterior line treatment of angiosarcoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 21, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>2 months</time_frame>
    <description>progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>2 months</time_frame>
    <description>objective response rat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>6 months</time_frame>
    <description>over survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>2 months</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>2 months</time_frame>
    <description>duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR</measure>
    <time_frame>2 months</time_frame>
    <description>time to response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>2 months</time_frame>
    <description>Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Fruquintinib in soft tissue sarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fruquintinib : 5mg, once a day (QD), oral on an empty stomach or after a meal, taken with 100 ~ 200ml drinking water for 3 weeks and stopped for 1 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib</intervention_name>
    <description>To observe the efficacy and safety of Fruquintinib in the first-line treatment of desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma or second-line and posterior line treatment of angiosarcoma.</description>
    <arm_group_label>Fruquintinib in soft tissue sarcoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Only those who meet all of the following criteria can be selected:&#xD;
&#xD;
          1. Fully understand this study and voluntarily sign the informed consent form;&#xD;
&#xD;
          2. Male or female subjects / patients aged ≥ 18 years;&#xD;
&#xD;
          3. Non operative desmoplastic small round cell tumor, epithelioid hemangioendothelioma,&#xD;
             solitary fibroma and angiosarcoma with failed chemotherapy confirmed by&#xD;
             histopathology;&#xD;
&#xD;
          4. Patients with desmoplastic small round cell tumor, epithelioid hemangioendothelioma,&#xD;
             solitary fibroma or angiosarcoma who failed to receive anti angiogenesis drugs in the&#xD;
             past.&#xD;
&#xD;
          5. At least one measurable lesion meeting the requirements of RECIST version 1.1; If the&#xD;
             focus that has previously received local treatment (radiotherapy, ablation, vascular&#xD;
             intervention, etc.) is the only focus, there must be a clear imaging basis for the&#xD;
             disease progression of the focus;&#xD;
&#xD;
          6. The ECoG score was 0 or 1;&#xD;
&#xD;
          7. The laboratory test results within 7 days before the first acceptance of the study&#xD;
             drug must meet the following criteria:&#xD;
&#xD;
        1) Neutrophil count ≥ 1.5 × 109 / L, platelet count ≥ 100 × 109 / L, hemoglobin ≥ 90 g / L&#xD;
        (no blood transfusion, no blood products, no granulocyte colony stimulating factor or other&#xD;
        hematopoietic stimulating factors within 7 days before laboratory examination);&#xD;
&#xD;
        2) Total serum bilirubin ≤ 1.5 × Upper normal value (ULN);&#xD;
&#xD;
        3) In the absence of liver metastasis, alanine aminotransferase (ALT) and aspartate&#xD;
        aminotransferase (AST) ≤ 1.5 × ULN； ALT and AST ≤ 3 in patients with liver metastasis or&#xD;
        liver cancer × ULN；［ Asymptomatic mild and moderate liver injury (defined as NCI CTCAE&#xD;
        grade 1 toxicity) and elevated ALT and AST &gt; 5 ~ 20 × Patients with ULN (NCI CTCAE Level 3)&#xD;
        may tolerate the same dose of study drugs as patients with normal liver function. Patients&#xD;
        with mild to moderate liver injury can be included on the premise that non clinical and&#xD;
        clinical data (including pharmacokinetic and pharmacokinetic results) suggest that there is&#xD;
        no unreasonable risk. If it is necessary to include patients with severe liver injury, it&#xD;
        is necessary to discuss with the regulatory authority]&#xD;
&#xD;
        4) Serum creatinine ≤ 1.5 × ULN and creatinine clearance ≥ 60 ml / min (calculated&#xD;
        according to Cockcroft Gault formula);&#xD;
&#xD;
        5) Urine routine examination showed that urinary protein was &lt; 2 +; If urinary protein ≥ 2&#xD;
        +, 24-hour urinary protein quantification should be &lt; 1 g;&#xD;
&#xD;
        6) International normalized ratio (INR) ≤ 1.5 and partially activated prothrombin time&#xD;
        (APTT) ≤ 1.5 × ULN。&#xD;
&#xD;
        8. Expected survival ≥ 12 weeks;&#xD;
&#xD;
        9. Agree to abide by the regulations on smoking, drinking, diet and exercise restrictions&#xD;
        during the study (which may cause more protocol violations, which shall be set according to&#xD;
        the needs of the study);&#xD;
&#xD;
        10. Female subjects / patients of childbearing age or male subjects / patients whose&#xD;
        partners are women of childbearing age shall take effective contraceptive measures, such as&#xD;
        double barrier contraceptive methods, condoms, intrauterine devices, abstinence, etc., from&#xD;
        at least 1 month before receiving the study drug for the first time to 6 months after&#xD;
        receiving the study drug for the last time.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Those who meet any of the following exclusion criteria must be excluded from the study:&#xD;
&#xD;
          1. The toxicity of previous anti-tumor treatment has not recovered ≤ grade 1 (except hair&#xD;
             loss, skin pigment change or neurotoxicity ≤ grade 2);&#xD;
&#xD;
          2. Other malignant tumors in the past 5 years (except skin basal cell carcinoma or&#xD;
             squamous cell carcinoma and cervical carcinoma in situ that have been effectively&#xD;
             controlled); (according to FDA guideline 1, patients with the same or different tumor&#xD;
             types who have been or are currently complicated with the same or different tumor&#xD;
             types, whose medical history or treatment has no potential impact on the safety or&#xD;
             efficacy evaluation of the study drug, should be included in the clinical study. For&#xD;
             example, patients with previous or current malignant tumors should not be excluded in&#xD;
             dose exploration, preliminary efficacy evaluation or proof of concept study)&#xD;
&#xD;
          3. There was central nervous system (CNS) metastasis in the past or screening, but the&#xD;
             primary central solitary fibrous tumor can be included in the group;&#xD;
&#xD;
          4. Have received approved systemic anti-tumor therapy within 4 weeks before receiving the&#xD;
             study drug for the first time, including chemotherapy (chemotherapy, biotherapy,&#xD;
             targeted therapy (the washout period of small molecule targeted drugs is 2 weeks or 5&#xD;
             half lives, whichever is shorter), hormone therapy and traditional Chinese medicine&#xD;
             therapy (for traditional Chinese medicine therapy with clear anti-tumor indications in&#xD;
             the instructions, it can be treated after 1 week washout period before the first&#xD;
             medication) Etc;&#xD;
&#xD;
          5. Radical radiotherapy (including more than 25% bone marrow radiotherapy) within 4 weeks&#xD;
             before receiving the study drug for the first time; brachytherapy (such as&#xD;
             implantation of radioactive particles) within 60 days before receiving the study drug&#xD;
             for the first time; palliative radiotherapy for bone metastases within 1 week before&#xD;
             receiving the study drug for the first time;&#xD;
&#xD;
          6. Major surgery (the definition of major surgery refers to grade 3 and 4 operations&#xD;
             specified in the measures for the administration of clinical application of medical&#xD;
             technology implemented on May 1, 2009) or unhealed wounds, ulcers and fractures within&#xD;
             4 weeks before receiving the study drug for the first time;&#xD;
&#xD;
          7. Prohibited combination drugs were used within 1 week before the first acceptance of&#xD;
             the study drug or within 5 drug half-life (whichever is longer)&#xD;
&#xD;
          8. Within the first 4 weeks of the first study, any live vaccine or attenuated vaccine&#xD;
             will be inoculated during the study period.&#xD;
&#xD;
          9. Previously received anti-angiogenic TKI drugs;&#xD;
&#xD;
         10. At present, there is uncontrolled malignant pleural effusion, ascites or pericardial&#xD;
             effusion (defined as that it cannot be effectively controlled by diuretics or puncture&#xD;
             according to the judgment of the researcher);&#xD;
&#xD;
         11. Gastrointestinal diseases such as gastric and duodenal active ulcer and ulcerative&#xD;
             colitis, or active bleeding of unresected tumors, or other conditions that may cause&#xD;
             gastrointestinal bleeding and perforation determined by the researcher before the&#xD;
             study;&#xD;
&#xD;
         12. Patients with evidence or history of thrombosis or obvious bleeding tendency within 2&#xD;
             months before receiving the study drug for the first time (bleeding &gt; 30 ml within 2&#xD;
             months, hematemesis, black stool and bloody stool), hemoptysis (fresh blood &gt; 5 ml&#xD;
             within 4 weeks);&#xD;
&#xD;
         13. Arterial thrombosis or deep venous thrombosis occurred within 6 months before the&#xD;
             first study drug; or thromboembolic events (including stroke events and / or transient&#xD;
             ischemic attack) occurred within 12 months;&#xD;
&#xD;
         14. Have active pulmonary tuberculosis, are receiving anti tuberculosis treatment or have&#xD;
             received anti tuberculosis treatment within 1 year before receiving the study drug for&#xD;
             the first time;&#xD;
&#xD;
         15. Patients with previous and current history of pulmonary fibrosis, interstitial&#xD;
             pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe&#xD;
             impairment of lung function and other patients who may interfere with the detection&#xD;
             and treatment of suspected drug-related pulmonary toxicity; radiation pneumonia in&#xD;
             radiotherapy area is allowed;&#xD;
&#xD;
         16. Hepatitis B virus (HBV) DNA&gt;1 is known to have clinically significant liver disease&#xD;
             history, including viral hepatitis active infection (hepatitis B surface antigen&#xD;
             HBsAg) and / or hepatitis B core antibody (HBcAb) positive. × 103 copies / ml or &gt;&#xD;
             2000 IU / ml; Hepatitis C virus (HCV) antibody is known to be positive and HCV RNA &gt; 1&#xD;
             × 103 copies / ml], or other hepatitis, clinically significant moderate and severe&#xD;
             liver cirrhosis;&#xD;
&#xD;
         17. Human immunodeficiency virus (HIV) antibody positive;&#xD;
&#xD;
         18. Meet any of the following criteria related to cardiac function:&#xD;
&#xD;
               -  Various clinically significant arrhythmias or conduction abnormalities require&#xD;
                  clinical intervention;&#xD;
&#xD;
               -  At rest, the QT interval (QTCF) of electrocardiogram (ECG) was &gt; 480 msec;&#xD;
&#xD;
             Note: if ECG cannot directly display QTCF results, please use the following formula&#xD;
             for calculation: QTCF = QT / ∛ RR&#xD;
&#xD;
             • Various clinically significant cardiovascular diseases, including acute myocardial&#xD;
             infarction, severe or unstable angina pectoris, coronary artery bypass grafting, New&#xD;
             York Heart Function Classification (NYHA) III / IV congestive heart failure,&#xD;
             ventricular arrhythmia requiring treatment, or left ventricular ejection fraction&#xD;
             (LVEF) &lt; 50% within 6 months before the first study.&#xD;
&#xD;
         19. Women who are known to be pregnant or breastfeeding;&#xD;
&#xD;
         20. Known history of allergy to the relevant components of the study drug;&#xD;
&#xD;
         21. Subjects / patients who participated in other intervention clinical studies within 4&#xD;
             weeks before the first acceptance of the study drug;&#xD;
&#xD;
         22. There is any disease or condition affecting drug absorption, or the subject / patient&#xD;
             cannot take the drug orally;&#xD;
&#xD;
         23. Those who have a history of psychotropic substance abuse and cannot quit or have&#xD;
             mental disorders;&#xD;
&#xD;
         24. For other reasons, the researcher judged that it was not suitable to participate in&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaowei Zhang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan Cancer Center，Shanghai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaowei Zhang, Doctor</last_name>
    <phone>021-64175590</phone>
    <phone_ext>88503</phone_ext>
    <email>dongfangzhizizhxw@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenxia Peng, Bachelor</last_name>
    <phone>021-64433755</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaowei Zhang, Doctor</last_name>
      <phone>021-64175590</phone>
      <phone_ext>520</phone_ext>
      <email>dongfangzhizizhxw@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 21, 2021</last_update_submitted>
  <last_update_submitted_qc>November 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>Fruquintinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

